Fatemeh Chalabianloo
Position
Associate Professor
Affiliation
- fatemeh.chalabianloo@uib.no
- Visitor address
-
Christies gate 12
5015 Bergen - Postal address
-
P.O. Box 7804NO-5020 BergenNorway
Fatemeh Chalabianloo
Position
Associate Professor
Affiliation
Research
Learn more about Fatemeh's work: Making methadone treatment better
Publications
Academic literature review
- Chalabianloo, Fatemeh; Fadnes, Lars T.; Johansson, Kjell Arne et al. (2024). Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications. (external link)
- Vold, Jørn Henrik; Aas, Christer Frode; Leiva, Rafael Alexander Mo et al. (2019). Integrated care of severe infectious diseases to people with substance use disorders; a systematic review. (external link)
Academic article
- Aas, Christer Frode; Vold, Jørn Henrik; Chalabianloo, Fatemeh et al. (2024). Effect of integrated hepatitis C virus treatment on psychological distress in people with substance use disorders. (external link)
- Vold, Jørn Henrik; Chalabianloo, Fatemeh; Løberg, Else-Marie et al. (2023). The efficacy of integrated hepatitis C virus treatment in relieving fatigue in people who inject drugs: a randomized controlled trial. (external link)
- Vold, Jørn Henrik; Halmøy, Anne; Chalabianloo, Fatemeh et al. (2023). Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study. (external link)
- Chalabianloo, Fatemeh; Høiseth, Gudrun; Vold, Jørn Henrik et al. (2022). Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations. (external link)
- Narasimha, Venkata Lakshmi; Butner, Jenna; Hanafi, Enjeline et al. (2022). Harm reduction and abstinence-based models for treatment of substance use disorders during the COVID-19 pandemic: a global perspective. (external link)
- Vold, Jørn Henrik; Chalabianloo, Fatemeh; Aas, Christer Frode et al. (2021). Changes in substance use during outpatient treatment for substance use disorders: a prospective Norwegian cohort study from 2016 to 2020. (external link)
- Chalabianloo, Fatemeh; Fadnes, Lars T.; Høiseth, Gudrun et al. (2021). Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway. (external link)
- Fadnes, Lars T.; Aas, Christer Frode; Vold, Jørn Henrik et al. (2021). Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). (external link)
- Chalabianloo, Fatemeh; Ohldieck, Christian; Haaland, Øystein Ariansen et al. (2021). Effectiveness and safety of low-threshold opioid-agonist treatment in hard-to-reach populations with opioid dependence. (external link)
- Vold, Jørn Henrik; Gjestad, Rolf; Aas, Christer Frode et al. (2020). Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020. (external link)
- Aas, Christer Frode; Vold, Jørn Henrik; Skurtveit, Svetlana et al. (2020). Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. (external link)
- Welle-Strand, Gabrielle; Skurtveit, Svetlana; Abel, Eli Kristine Fiksdal et al. (2020). Living a normal life? Follow-up study of women who had been in opioid maintenance treatment during pregnancy. (external link)
- Aas, Christer Frode; Vold, Jørn Henrik; Skurtveit, Svetlana et al. (2020). On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: A prospective cohort study from 2013 to 2017. (external link)
- Vold, Jørn Henrik; Aas, Christer Frode; Skurtveit, Svetlana et al. (2020). Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017. (external link)
- Vold, Jørn Henrik; Aas, Christer Frode; Skurtveit, Svetlana et al. (2020). Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; A national prospective cohort study in Norway from 2015 to 2017. (external link)
- Vold, Jørn Henrik; Skurtveit, Svetlana; Aas, Christer Frode et al. (2020). Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; A prospective cohort study in Norway from 2013 to 2017. (external link)
- Chalabianloo, Fatemeh; Westin, Andreas; Skogvoll, Eirik et al. (2019). Methadone serum concentrations and influencing factors: A naturalistic observational study. (external link)
- Fadnes, Lars T.; Aas, Christer Frode; Vold, Jørn Henrik et al. (2019). Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). (external link)
- Kringen, Marianne K.; Chalabianloo, Fatemeh; Bernard, Jean-Paul Anthony et al. (2017). Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment. (external link)
- Chalabianloo, Fatemeh; Berstad, Aud K Herland; Schjøtt, Jan et al. (2011). Clinical characteristics of patients with drug hypersensitivity in Norway: a single-centre study. (external link)